Micrologix biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Carter Berezay who wrote (500)	5/22/1999 7:56:00 PM
From: Carter Berezay	Read Replies (2) of 792

ALL, It's out! MBI is now being covered by TD Securities - a subsidiary of the TD Bank. Their 12 month target is $4.50/share. It is a well-written report - about 13 pages. It is very comprehensive and well worth the read. It says the competition for the development of multi-drug resistant solutions is very limited. It looks like MBI is not going to be blown out of the market at all. Some other things. Two of the largest USA infectious disease healthcare expenses are for the treatment of AIDS and tuberculosis. In 1993, the WHO viewed the threat of the multi-drug resistant TB as a global emergency. The report puts no stock in MBI's "secret" drug. They acknowledge it exists and that's about it. It is a very good report but the thing is not the 12 month $4.50 price they put on MBI, it is the fact that MBI is now being covered by a major company that has some influence in the "institution" industry. MBI has always suffered from a lack of exposure in the market. Maybe this report is the start of major things to come for this company. Good luck to all. Carter B.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next